Mayo Clinic Laboratory and pathology research roundup: December 14

By Chantell Canfield • December 14, 2021

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Renal Neoplasia in Polycystic Kidney Disease: An assessment of Tuberous Sclerosis complex-associated Renal Neoplasia and PKD1/TSC2 contiguous gene deletion syndrome.

To determine the incidence of renal neoplasia among patients undergoing nephrectomy for polycystic kidney disease (PKD), we queried our institutional nephrectomy registry (years 2000-2020). Approximately 4% (231 of 5757) of patients who underwent nephrectomy had PKD, and 26 of these 231 patients (11.3%) had renal neoplasia. Tumors from an additional two patients with PKD were also evaluated. Patients with PKD who had tuberous sclerosis complex (TSC)-associated renal neoplasia were screened for PKD1/TSC2 contiguous gene deletion syndrome (CGS) using single nucleotide polymorphism arrays. The median age of patients with PKD and renal neoplasia at nephrectomy was 54 yr. The median tumor size was 2.0 cm and the tumors were predominantly of low grade and stage. The tumors consisted of 23 renal cell carcinomas (RCCs), one epithelioid angiomyolipoma, and four angiomyolipomas. The median follow-up was 59.5 mo (n = 26) and only one patient with clear cell RCC developed metastases. Two patients with angiomyolipomas had PKD1/TSC2 CGS. Our results support screening of patients with PKD and TSC-associated renal neoplasia as well as TSC patients with cystic renal disease for CGS, as identification of patients with CGS can better define the manifestation and prognosis of CGS and guide counseling regarding patterns of inheritance. PATIENT SUMMARY: We identified patients with abnormal kidney cell growth (called renal neoplasia) among those undergoing removal of kidney tissue for polycystic kidney disease (PKD) and patients with a syndrome involving deletions in two genes, called PKD1/TSC2 contiguous gene deletion syndrome (CGS) at our institution. Of 231 PKD patients with removal of kidney tissue, 11.3% had renal neoplasia, and two patients with angiomyolipoma tumors had PKD1/TSC2 CGS. Detection of renal neoplasia associated with a condition called tuberous sclerosis complex in PKD may increase the identification of patients with PKD1/TSC2 CGS and guide patient counseling regarding outcomes and patterns of inheritance.

Read more.

Published to PubMed This Week

• The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice.
  Nature Metabolism
• Acute treatment effects on GFR in randomized clinical trials of kidney disease progression.
  Journal of the American Society of Nephrology
• Anti-cachectic regulator analysis reveals novel Perp-dependent anti-tumorigenic properties of 3-methyladenine in pancreatic cancer.
  JCI Insight
• Adrenal Myelolipoma.
  Mayo Clinic Proceedings
• The tale of TILs in breast cancer: A report from the international immuno-Oncology biomarker working group.
  NPJ Breast Cancer
• A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of acute Myeloid Leukemia patients.
  Blood Advances
• Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction.
  ESC Heart Failure
• Clinical and echocardiographic characteristics of patients with pathology proven right-sided papillary fibroelastomas.
  International Journal of Cardiology
• Overfeeding-induced weight gain elicits decreases in sex hormone-binding globulin in healthy males-Implications for body fat distribution.
  Physiological Reports
• The first case of Janibacter hoylei bacteremia in an adult.
  IDcases

Chantell Canfield

Chantell Canfield is a web content coordinator for Mayo Clinic Laboratories. She began working for Mayo Clinic in 2021.